These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38968490)

  • 21. Short term effectiveness of ustekinumab versus vedolizumab in Crohn's disease after failure of anti-TNF agents: An observational comparative study design with a Bayesian analysis.
    Alamer A; Al Lehaibi LH; Alomar M; Aldhuwayan F; Alshouish S; Al-Ali AY; Almudhry Z; Almulhim A; Althagafi A; Aldosari S; AlAmeel T
    Saudi J Gastroenterol; 2024 Sep; 30(5):324-334. PubMed ID: 39157885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn's Disease.
    Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W; Narula N
    Inflamm Bowel Dis; 2023 Jul; 29(7):1015-1023. PubMed ID: 35920382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort.
    Ma C; Fedorak RN; Kaplan GG; Dieleman LA; Devlin SM; Stern N; Kroeker KI; Seow CH; Leung Y; Novak KL; Halloran BP; Huang VW; Wong K; Blustein PK; Ghosh S; Panaccione R
    Aliment Pharmacol Ther; 2017 May; 45(9):1232-1243. PubMed ID: 28252210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
    Rutgeerts P; Gasink C; Chan D; Lang Y; Pollack P; Colombel JF; Wolf DC; Jacobstein D; Johanns J; Szapary P; Adedokun OJ; Feagan BG; Sandborn WJ
    Gastroenterology; 2018 Oct; 155(4):1045-1058. PubMed ID: 29909019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy, drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab - A prospective, multicenter cohort from Hungary.
    Gonczi L; Szanto K; Farkas K; Molnar T; Szamosi T; Schafer E; Golovics PA; Barkai L; Lontai L; Lovasz B; Juhasz M; Patai A; Sarang K; Vincze A; Sarlos P; Farkas A; Dubravcsik Z; Toth TG; Miheller P; Ilias A; Lakatos PL
    Dig Liver Dis; 2022 Feb; 54(2):207-213. PubMed ID: 34344576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postoperative Ustekinumab Drug Levels and Disease Activity in Patients with Crohn's Disease.
    Moskow J; Thurston T; Saleh A; Shah A; Abraham BP; Glassner K
    Dig Dis Sci; 2024 Aug; 69(8):2944-2954. PubMed ID: 38789673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.
    Biemans VBC; van der Woude CJ; Dijkstra G; van der Meulen-de Jong AE; Löwenberg M; de Boer NK; Oldenburg B; Srivastava N; Jansen JM; Bodelier AGL; West RL; de Vries AC; Haans JJL; de Jong D; Hoentjen F; Pierik MJ;
    Aliment Pharmacol Ther; 2020 Jul; 52(1):123-134. PubMed ID: 32441396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
    Danese S; Panaccione R; Feagan BG; Afzali A; Rubin DT; Sands BE; Reinisch W; Panés J; Sahoo A; Terry NA; Chan D; Han C; Frustaci ME; Yang Z; Sandborn WJ; Hisamatsu T; Andrews JM; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2024 Feb; 9(2):133-146. PubMed ID: 38104569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
    Danese S; Vermeire S; D'Haens G; Panés J; Dignass A; Magro F; Nazar M; Le Bars M; Lahaye M; Ni L; Bravata I; Lavie F; Daperno M; Lukáš M; Armuzzi A; Löwenberg M; Gaya DR; Peyrin-Biroulet L;
    Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):294-306. PubMed ID: 35120656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease.
    Painchart C; Brabant S; Duveau N; Nachury M; Desreumaux P; Branche J; Gérard R; Prevost CLD; Wils P; Lambin T; Boualit M; Labalette M; Pariente B
    Dig Dis Sci; 2020 May; 65(5):1445-1452. PubMed ID: 31599389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn's disease.
    Hirayama H; Morita Y; Imai T; Takahashi K; Yoshida A; Bamba S; Inatomi O; Andoh A
    BMC Gastroenterol; 2022 Apr; 22(1):195. PubMed ID: 35448957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study.
    Bar-Gil Shitrit A; Ben-Ya'acov A; Siterman M; Waterman M; Hirsh A; Schwartz D; Zittan E; Adler Y; Koslowsky B; Avni-Biron I; Chowers Y; Ron Y; Israeli E; Ungar B; Yanai H; Maharshak N; Ben-Horin S; Eliakim R; Dotan I; Goldin E; Kopylov U
    United European Gastroenterol J; 2020 May; 8(4):418-424. PubMed ID: 32213026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship Between Serum Ustekinumab Trough Concentration and Clinical and Biochemical Disease Activity: A Real-World Study in Adult Patients with Crohn's Disease.
    Nguyen KM; Mattoo VY; Vogrin S; Basnayake C; Connell WR; Ding NS; Flanagan E; Kamm MA; Lust M; Niewiadomski O; Schulberg JD; Wright EK
    Eur J Drug Metab Pharmacokinet; 2023 May; 48(3):271-279. PubMed ID: 36952135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn's disease patients over three years.
    Barkai LJ; Gonczi L; Balogh F; Angyal D; Farkas K; Farkas B; Molnar T; Szamosi T; Schafer E; Golovics PA; Juhasz M; Patai A; Vincze A; Sarlos P; Farkas A; Dubravcsik Z; Toth TG; Szekely H; Miheller P; Lakatos PL; Ilias A
    Sci Rep; 2024 Jun; 14(1):14909. PubMed ID: 38942890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ustekinumab Tissue and Serum Levels in Patients With Crohn's Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction.
    Proietti E; Pauwels RWM; van der Woude CJ; Doukas M; Oudijk L; Peppelenbosch MP; Grohmann U; Crombag MBS; de Vries AC; Fuhler GM
    Inflamm Bowel Dis; 2023 Jul; 29(7):1038-1046. PubMed ID: 35917118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Ustekinumab Optimization by 2 Initial Intravenous Doses in Adult Patients With Severe Crohn's Disease.
    Ren H; Kang J; Wang J; Su J; Zou L; Yin A; Li J; Zhou Q; Wang W; Tang Z; Zhang J; Lu Y; Yang Y; Qiu C; Ding Y; Dong W; An P
    Inflamm Bowel Dis; 2024 Aug; 30(8):1295-1302. PubMed ID: 37619248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ustekinumab induction concentrations are associated with clinical and biochemical outcomes at week 12 of treatment in Crohn's disease.
    Walshe M; Borowski K; Boland K; Rho S; Stempak JM; Silverberg MS
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e401-e406. PubMed ID: 33731595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical remission and transmural healing of ustekinumab in patients with Crohn's disease].
    Wu Y; Xu Y; Zhang G; Zhang Y; Wang J; You P; Peng T; Liu Y; Chen N
    Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Apr; 56(2):253-259. PubMed ID: 38595241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting Endoscopic Crohn's Disease Activity Before and After Induction Therapy in Children: A Comprehensive Assessment of PCDAI, CRP, and Fecal Calprotectin.
    Zubin G; Peter L
    Inflamm Bowel Dis; 2015 Jun; 21(6):1386-91. PubMed ID: 25851564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
    Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.